Jacinth Wing-Sum Cheu

Jacinth Wing-Sum Cheu

Auto-generated profile, based on publicly available information

Jacinth Wing-Sum Cheu

The University of Hong Kong Li Ka Shing Faculty of Medicine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in Science Advances
Verified
Journal Article
Open access
JCJacinth Wing-Sum Cheu
Jacinth Wing-Sum Cheu
DCDavid Kung-Chun Chiu
David Kung-Chun Chiu
KKKenneth Kin-Leung Kwan
Kenneth Kin-Leung Kwan
CYChunxue Yang
Chunxue Yang
VYVincent Wai-Hin Yuen
Vincent Wai-Hin Yuen
CWCarmen Chak‐Lui Wong
Carmen Chak‐Lui Wong
Hypoxia-induced adenosine creates an immunosuppressive tumor microenvironment (TME) and dampens the efficacy of immune checkpoint inhibitors (ICIs). We found that hypoxia-inducible factor 1 (HIF-1) orchestrates adenosine efflux through two steps in hepatocellular carcinoma (HCC). First, HIF-1 activates transcriptional repressor MXI1, which inhibits adenosine kinase (ADK), resulting in the failure of adenosine phosphorylation to adenosine monophosphate. This leads to adenosine accumulation in hypoxic cancer cells. Second, HIF-1 transcriptionally activates equilibrative nucleoside transporter 4, pumping adenosine into the interstitial space of HCC, elevating extracellular adenosine levels. Multiple in vitro assays demonstrated the immunosuppressive role of adenosine on T cells and myeloid cells. Knockout of ADK in vivo skewed intratumoral immune cells to protumorigenic and promoted tumor progression. Therapeutically, combination treatment of adenosine receptor antagonists and anti–PD-1 prolonged survival of HCC-bearing mice. We illustrated the dual role of hypoxia in establishing an adenosine-mediated immunosuppressive TME and offered a potential therapeutic approach that synergizes with ICIs in HCC.

22 November 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
PWPo Yee Wong
Po Yee Wong
CCCerise Yuen Ki Chan
Cerise Yuen Ki Chan
HXHelen Do Gai Xue
Helen Do Gai Xue
CGChi Ching Goh
Chi Ching Goh
JCJacinth Wing Sum Cheu
Jacinth Wing Sum Cheu
CWCarmen Chak‐Lui Wong
Carmen Chak‐Lui Wong
Cell cycle inhibitors have a long history as cancer treatment. Here, we reported that these inhibitors combated cancer partially via Stimulator of IFN genes (STING) signaling pathway. We demonstrated that Paclitaxel (microtubule stabilizer), Palbociclib (cyclin dependent kinase 4/6 inhibitor), AZD1152 and GSK1070916 (aurora kinase B inhibitors) have anti-cancer functions beyond arresting cell cycle. They consistently caused cytosolic DNA accumulation and DNA damage, which inadvertently triggered the cytosolic DNA sensor DEAD-box helicase 41 (DDX41) and activated STING to secrete pro-inflammatory senescence-associated secretory phenotype factors (SASPs). Interestingly, we found that DDX41 was a transcriptional target of HIF. Hypoxia induced expression of DDX41 through HIF-1, making hypoxic HCC cells more sensitive to the anti-mitotic agents in STING activation and SASP production. The SASPs triggered immune cell infiltration in tumors for cancer clearance. The treatment of cell cycle inhibitors, especially Paclitaxel, extends survival by perturbing mouse HCC growth when used in combination with anti-PD-1. We observed a trend that Paclitaxel suppressed STINGWT HCC more effectively than STINGKO HCC, suggesting that STING might contribute to the anti-tumor effects of Paclitaxel. Our study revealed the immune-mediated tumor-suppressing properties of cell cycle inhibitors and suggested combined treatment with immunotherapy as a potential therapeutic approach.

1 September 2024 in Hepatology Communications
Verified
Journal Article
Open access
JCJacinth Wing-Sum Cheu
Jacinth Wing-Sum Cheu
CWCarmen Chak‐Lui Wong
Carmen Chak‐Lui Wong
Hepatocellular carcinoma (HCC), the major type of primary liver cancer, is notorious for its resistance to systemic treatments. The field has made a great leap in the past decade, with the number of FDA-approved therapies for advanced HCC increasing from 1 to 9. Although tyrosine kinase inhibitors remain the most common first-line option as monotherapy treatment, the clinical success of immune checkpoint inhibitors, especially when used in combination with anti-VEGF/VEGFR in HCC will likely transform the treatment landscape. While immune checkpoint inhibitors represent an exciting therapeutic revenue for HCC, recent studies have revealed that nonviral HCC, which is primarily caused by metabolic dysfunction–associated steatotic hepatitis (MASH), has a distinct and less favorable response to the immune checkpoint inhibitors. MASH is the most rapidly increasing etiology for HCC. The immune microenvironment of MASH-HCC is greatly affected by the intertwined pathological processes of steatosis-induced iterative cycles between steatohepatitis and liver injury. Here, we present a timely summary of the immune microenvironment of MASH-HCC. We will delve into the use of cutting-edge technologies, such as single-cell RNA sequencing, spatial transcriptomics, and mass cytometry imaging, to deconvolute the complexity of the immune ecosystem in MASH-HCC. We will also discuss the novel therapeutic innovations for MASH-HCC in preclinical models, such as the metabolic inhibitor, epigenetic inhibitor, and immunomodulator. These inhibitors all have the ability to subvert the immune microenvironment of MASH-HCC, improving the efficiency of anti-PD-1. While awaiting new drugs to be tested in clinical trials, the knowledge gained from these investigations is crucial for the development of personalized and effective treatment strategies for MASH-HCC.

15 December 2025 in Cancer Research
Verified
Journal Article
Closed access
JLJiin Lee
Jiin Lee
JCJacinth Wing-Sum Cheu
Jacinth Wing-Sum Cheu
CWCarmen Chak‐Lui Wong
Carmen Chak‐Lui Wong
Lipid metabolism reprogramming modulates the tumor microenvironment (TME) and alters the function of immune cells, including tumor-infiltrating lymphocytes (TIL). Although lipids can enhance general T-cell activity, high lipid content in the TME may restrain the antitumor function of effector T cells and augment immunosuppression by regulatory T cells. In addition, lipid metabolism reprogramming greatly influences the cross-talk between TILs and other immune cells in the TME, including dendritic cells, macrophages, and myeloid-derived suppressor cells. By discussing potential therapeutic strategies to target lipid metabolism in TILs, along with combination approaches with chemo-immunotherapy, nanomedicine, and adoptive cell transfer therapy, we aim to lay the groundwork for advancing effective treatments for patients with cancer.

23 September 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
HNHiu-Lok NGAN
Hiu-Lok NGAN
JZJialing Zhang
Jialing Zhang
KKKenneth Kin-Leung Kwan
Kenneth Kin-Leung Kwan
JCJacinth Wing-Sum Cheu
Jacinth Wing-Sum Cheu
LZLi Zhong
Li Zhong
ZCZongwei Cai
Zongwei Cai
Machine learning (ML) modeling on mass spectrometry (MS)-based shotgun data facilitates feature selection and disease modeling. However, batch-specific models often struggle with limited transferability and generalizability, necessitating data integration from multiple batches and platforms. Traditional binning methods can either disintegrate or aggregate m/z features, making data combination unreliable. In this study, we introduce a mass resolution-adaptive binning and integration strategy to overcome these challenges. This approach recovers 88–99 % of ground truth features in a low mass region (70–434 m/z) from 250, 500, and 1000 ppb of 49 mixed standard solutions. Compared to conventional methods, it demonstrates stable binning and integration across low (100–450 m/z), mid (450–900 m/z), and high (900–1500 m/z) mass regions, resulting in superior predictive models. Using a mouse model of hepatocellular carcinoma as a proof-of-concept study, we identify 10 generic metabolites that showcase advancements in using ambient MS imaging (MSI) data for modeling and deploy the attained model to shotgun data. This facilitates disease detection via various sample introduction methods, including MSI on liver cryosections (F1 score = 0.87) and glass smears (F1 score = 0.80), as well as rapid direct infusion analysis (recall = 0.89 and precision = 0.63). This novel mass resolution-adaptive binning and integration strategy offers a promising approach for integrating different datasets, potentially improving disease detection accuracy in MS applications.

12 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HNHiu-Lok NGAN
Hiu-Lok NGAN
JCJacinth Wing-Sum Cheu
Jacinth Wing-Sum Cheu
KKKenneth Kin-Leung Kwan
Kenneth Kin-Leung Kwan
CWCarmen Chak‐Lui Wong
Carmen Chak‐Lui Wong
HYHong Yan
Hong Yan
ZCZongwei Cai
Zongwei Cai
Chronic liver fibrosis significantly increases the risk of hepatocellular carcinoma (HCC), a leading cause of cancer-related deaths. However, the molecular mechanisms linking fibrosis to inflammation-associated HCC development remain unclear, complicating early diagnosis and intervention. In this study, we employ multi-omics analyses, including untargeted and targeted metabolomics, lipidomics, and transcriptomics, in a mouse model of chemically induced liver fibrosis and HCC, integrating publicly available transcriptome data from LX-2 human hepatic stellate cell (HSC) line. Our results reveal a profound rewiring of NAD+ metabolism as a central driver of metabolic disturbance. Analysis of bulk liver tissue shows increased activity of the kynurenine pathway of tryptophan metabolism, enhancing NAD+ precursor production. Hepatic nicotinamide (NAM) levels decrease due to elevated expression of NAM N-methyltransferase (Nnmt) in HSCs. Despite reduced hepatic NAM, serum NAD+ level rise and is compartmentalized, triggering a disruption in NAD+ homeostasis and activating NF-κB-mediated oxidative stress pathways. Moreover, lipid dysregulation occurs, with NF-κB dominating the regulation of SIRT1/SREBP-controlled lipogenic and cholesterogenic genes, leading to imbalances in hepatic and serum lipids. These insights elucidate connections between NAD+ metabolism, inflammation, and lipid dysregulation, potentially aiding in developing diagnostic biomarkers and therapeutic targets for non-viral HCC.